Rättelse: Till Aktieägarna i IDL Biotech AB, angående inlösen av återstående aktier
Detta pressmeddelande är en korrigering av information i tidigare brev, kungörelse och pressmeddelande från IDL Biotech AB och ersätter densamma.
Per-Anders Abrahamsson, MD, PhD, Professor in Urology, has been working as urologist for 40 years, out of which 20 years as Head of the Department of Urology, Skåne University Hospital (Malmö/Lund, Trelleborg and Landskrona), Adjunct Secretary General at the European Association of Urology (EAU) 2004-2007 responsible for Science, EAU Secretary General 2007 – 2015, Vice President Global Medical Affairs Uro-oncology, Ferring Pharmaceuticals A/S and Member of the Board at Camurus AB.
Per-Anders Abrahamsson has over 40 years experience of translational and clinical research, management and political experience in Urology. Professor Abrahamsson is also an Adjunct Professor in Urology at the University of Rochester Medical Center, New York, USA, and Adjunct Professor at the Russian Institute of Urology, Moscow, Russia.
Professor Abrahamsson is Honorary Professor at 16 Institutions all over the world.
He has received numerous awards and The Polish Red Cross for humanitarian support
and several prizes for presentations at International Meetings.
As Scientific Advisor to IDL Biotech, Per-Anders Abrahamsson will contribute with his
experience and expertise. He will strengthen the company clinical studies, and
contribute as medical advisor on development of new products in the area of oncology and urology.
“I’m pleased to welcome Professor Abrahamsson to IDL Biotech. His wealth of
knowledge and experience will be of great benefit to our company,” says Charlotte
Berg, CEO at IDL Biotech AB.
“Professor Abrahamsson is the right person to contribute to the development of the
potential in our products”, says Hans Örström, chairman of the Board.
Through the election of Per-Anders Abrahamsson, IDL Biotech AB will strengthen its national competence in urology and oncology, in addition to obtaining access to an extensive international network. This will be advantageous in relation to planned expansion phase, both on the current markets in Europe, and globally.
AroCell AB, äger numer mer än 90 procent av aktierna i IDL Biotech AB, och har beslutat att använda sin rätt enligt 22 kap. 1 § aktiebolagslagen (2005:551) att lösa in återstående aktier i IDL Biotech.